Viridian Q4 Revenue $132K, Below Consensus $15.75M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy VRDN?
Reports Q4 revenue $132,000, consensus $15.75M. "We enter 2026 with the momentum of our continued execution," said Steve Mahoney, president and CEO of Viridian. "With the veligrotug BLA filing under Priority Review and a PDUFA target date of June 30, 2026, we are well-prepared for our potential first commercial launch, a significant milestone for the company and for patients with TED. The submission of our MAA to the EMA supports the long-term, global opportunity for veligrotug. We are advancing toward reporting pivotal REVEAL-1 topline data for elegrobart next month, which we believe has the potential to be a best-in-class subcutaneous therapy for TED patients. Our goal is to establish veligrotug and elegrobart as foundational therapies for TED, while driving our pipeline forward to address additional indications and unmet needs."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VRDN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VRDN
Wall Street analysts forecast VRDN stock price to rise
17 Analyst Rating
17 Buy
0 Hold
0 Sell
Strong Buy
Current: 29.320
Low
14.20
Averages
41.71
High
61.00
Current: 29.320
Low
14.20
Averages
41.71
High
61.00
About VRDN
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. It is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Viridian Therapeutics Q4 Earnings Report Analysis
- Disappointing Earnings: Viridian Therapeutics reported a Q4 GAAP EPS of -$1.08, missing expectations by $0.08, indicating challenges in profitability that could undermine investor confidence.
- Weak Revenue Growth: Although revenue surged 85.7% year-over-year to $0.13M, it fell short of expectations by $15.62M, reflecting weaker-than-anticipated market demand that may hinder future business development.
- Strong Balance Sheet: As of December 31, 2025, the company boasts cash, cash equivalents, and short-term investments totaling $875 million, demonstrating solid liquidity to support future R&D and operations.
- Cautious Market Outlook: Despite financial challenges, there is cautious optimism in the market regarding Viridian Therapeutics as key milestones approach, potentially opening new avenues for growth for the company.
See More
Commodore Capital Fully Exits Viridian Therapeutics Position
- Position Liquidation: On February 17, 2026, Commodore Capital disclosed in an SEC filing that it sold its entire 3.2 million shares of Viridian Therapeutics for approximately $69.06 million, indicating a potential loss of confidence in the company.
- Portfolio Adjustment: The liquidation reduced Viridian's weighting from 3.4% of Commodore's 13F AUM to zero, suggesting a strategic shift in investment focus, possibly favoring other promising pipelines in the biotech sector.
- Market Performance: As of February 17, 2026, Viridian's shares were priced at $28.29, reflecting a 75% increase over the past year; however, Commodore's exit may indicate a recalibration of risk ahead of significant upcoming catalysts.
- Future Outlook: Viridian is poised for multiple potential catalysts in 2026, including FDA reviews for its thyroid eye disease treatment, yet Commodore's exit may reflect a cautious stance on the company's future performance amid clinical-stage risks.
See More
Commodore Capital Exits Entire Position in Viridian Therapeutics
- Complete Share Exit: Commodore Capital disclosed on February 17, 2026, that it sold its entire 3,200,000 shares of Viridian Therapeutics, resulting in a $69.06 million decrease in net position value, indicating a potential loss of confidence in the company.
- Portfolio Adjustment: The sale reduced Viridian's weight in Commodore's portfolio from 3.4% to 0%, reflecting a reassessment of the company's future risks, particularly in light of the upcoming catalyst-heavy year.
- Market Outlook Analysis: Viridian is entering a catalyst-rich year with the FDA accepting its BLA for veligrotug for thyroid eye disease, set for review on June 30, yet Commodore's exit may signal concerns over short-term stock volatility.
- Financial Status Overview: As of the end of October, Viridian had approximately $888 million in cash and investments and expects to fund operations through profitability, but Commodore's exit could undermine market confidence in its future growth potential.
See More
Biotech Stocks Surge in 2025 with $30.9 Billion M&A Wave
- M&A Surge: In 2025, small and mid-cap biopharma companies accounted for 57% of acquisitions by deal count, with 33 deals totaling $30.9 billion, indicating a significant recovery in market confidence despite a drop in median deal value from $516 million to $303 million.
- Shift in Investor Focus: Investor attention has shifted from GLP-1 obesity drugs to cancer and autoimmune disease treatments in 2025, particularly next-generation cell therapies, reflecting strong demand for innovative treatment options and potential growth opportunities in the biotech sector.
- Strong Clinical Data: Approximately $6 billion in acquisitions related to next-generation cell therapies occurred over the past six months, highlighting significant interest from big pharma in this niche, which could drive stock price increases for involved companies.
- Optimistic Outlook: Analysts expect increased M&A and strategic partnerships in 2026, particularly in immunology and rare diseases, with a lower interest rate environment improving funding conditions and further supporting the growth of biotech companies.
See More
Viridian Therapeutics (VRDN) Secures FDA Priority Review for Veligrotug in Thyroid Eye Disease
- FDA Priority Review: Viridian Therapeutics' Biologics License Application for Veligrotug has been accepted for priority review by the FDA, with a decision expected by June 30, 2026, which will expedite its entry into the thyroid eye disease treatment market to meet growing patient needs.
- Clinical Trial Success: Veligrotug met all primary and secondary endpoints in the THRIVE and THRIVE 2 phase 3 clinical trials, demonstrating significant improvement in chronic thyroid eye disease patients' diplopia symptoms, with rapid clinical benefits enhancing its market competitiveness.
- Breakthrough Therapy Designation: In May 2025, the FDA granted Veligrotug breakthrough therapy designation, indicating its potential in treating thyroid eye disease, which further elevates investor and market interest in the drug.
- European Market Plans: Viridian plans to submit a Marketing Authorisation Application to the European Medicines Agency in the first quarter of 2026, reflecting its strategic intent for global expansion and aiming to capture growth opportunities in international markets.
See More
Argenx Suspends Phase 3 Trial for Thyroid Eye Disease, Opening Opportunities for Competitors Like Viridian Therapeutics
Discontinuation of Phase 3 Studies: Argenx SE has decided to halt the Phase 3 UplighTED studies of efgartigimod for moderate to severe thyroid eye disease after an Independent Data Monitoring Committee recommended stopping the trials for futility based on interim analysis data.
Safety Profile: Despite the discontinuation, efgartigimod demonstrated a favorable safety and tolerability profile, with no new safety signals identified during the trials.
Future Data Analysis: Following the closure of the studies, Argenx plans to conduct a comprehensive analysis of the collected data, which will be shared at a future medical meeting.
Market Impact: The announcement surprised analysts, with some noting that the news could positively affect the IGF-1R antibody class, while Argenx shares fell by nearly 5% following the news.
See More
Viridian Therapeutics Q4 Earnings Report Analysis
- Disappointing Earnings: Viridian Therapeutics reported a Q4 GAAP EPS of -$1.08, missing expectations by $0.08, indicating challenges in profitability that could undermine investor confidence.
- Weak Revenue Growth: Although revenue surged 85.7% year-over-year to $0.13M, it fell short of expectations by $15.62M, reflecting weaker-than-anticipated market demand that may hinder future business development.
- Strong Balance Sheet: As of December 31, 2025, the company boasts cash, cash equivalents, and short-term investments totaling $875 million, demonstrating solid liquidity to support future R&D and operations.
- Cautious Market Outlook: Despite financial challenges, there is cautious optimism in the market regarding Viridian Therapeutics as key milestones approach, potentially opening new avenues for growth for the company.
See More
Commodore Capital Fully Exits Viridian Therapeutics Position
- Position Liquidation: On February 17, 2026, Commodore Capital disclosed in an SEC filing that it sold its entire 3.2 million shares of Viridian Therapeutics for approximately $69.06 million, indicating a potential loss of confidence in the company.
- Portfolio Adjustment: The liquidation reduced Viridian's weighting from 3.4% of Commodore's 13F AUM to zero, suggesting a strategic shift in investment focus, possibly favoring other promising pipelines in the biotech sector.
- Market Performance: As of February 17, 2026, Viridian's shares were priced at $28.29, reflecting a 75% increase over the past year; however, Commodore's exit may indicate a recalibration of risk ahead of significant upcoming catalysts.
- Future Outlook: Viridian is poised for multiple potential catalysts in 2026, including FDA reviews for its thyroid eye disease treatment, yet Commodore's exit may reflect a cautious stance on the company's future performance amid clinical-stage risks.
See More
Commodore Capital Exits Entire Position in Viridian Therapeutics
- Complete Share Exit: Commodore Capital disclosed on February 17, 2026, that it sold its entire 3,200,000 shares of Viridian Therapeutics, resulting in a $69.06 million decrease in net position value, indicating a potential loss of confidence in the company.
- Portfolio Adjustment: The sale reduced Viridian's weight in Commodore's portfolio from 3.4% to 0%, reflecting a reassessment of the company's future risks, particularly in light of the upcoming catalyst-heavy year.
- Market Outlook Analysis: Viridian is entering a catalyst-rich year with the FDA accepting its BLA for veligrotug for thyroid eye disease, set for review on June 30, yet Commodore's exit may signal concerns over short-term stock volatility.
- Financial Status Overview: As of the end of October, Viridian had approximately $888 million in cash and investments and expects to fund operations through profitability, but Commodore's exit could undermine market confidence in its future growth potential.
See More
Biotech Stocks Surge in 2025 with $30.9 Billion M&A Wave
- M&A Surge: In 2025, small and mid-cap biopharma companies accounted for 57% of acquisitions by deal count, with 33 deals totaling $30.9 billion, indicating a significant recovery in market confidence despite a drop in median deal value from $516 million to $303 million.
- Shift in Investor Focus: Investor attention has shifted from GLP-1 obesity drugs to cancer and autoimmune disease treatments in 2025, particularly next-generation cell therapies, reflecting strong demand for innovative treatment options and potential growth opportunities in the biotech sector.
- Strong Clinical Data: Approximately $6 billion in acquisitions related to next-generation cell therapies occurred over the past six months, highlighting significant interest from big pharma in this niche, which could drive stock price increases for involved companies.
- Optimistic Outlook: Analysts expect increased M&A and strategic partnerships in 2026, particularly in immunology and rare diseases, with a lower interest rate environment improving funding conditions and further supporting the growth of biotech companies.
See More
Viridian Therapeutics (VRDN) Secures FDA Priority Review for Veligrotug in Thyroid Eye Disease
- FDA Priority Review: Viridian Therapeutics' Biologics License Application for Veligrotug has been accepted for priority review by the FDA, with a decision expected by June 30, 2026, which will expedite its entry into the thyroid eye disease treatment market to meet growing patient needs.
- Clinical Trial Success: Veligrotug met all primary and secondary endpoints in the THRIVE and THRIVE 2 phase 3 clinical trials, demonstrating significant improvement in chronic thyroid eye disease patients' diplopia symptoms, with rapid clinical benefits enhancing its market competitiveness.
- Breakthrough Therapy Designation: In May 2025, the FDA granted Veligrotug breakthrough therapy designation, indicating its potential in treating thyroid eye disease, which further elevates investor and market interest in the drug.
- European Market Plans: Viridian plans to submit a Marketing Authorisation Application to the European Medicines Agency in the first quarter of 2026, reflecting its strategic intent for global expansion and aiming to capture growth opportunities in international markets.
See More
Argenx Suspends Phase 3 Trial for Thyroid Eye Disease, Opening Opportunities for Competitors Like Viridian Therapeutics
Discontinuation of Phase 3 Studies: Argenx SE has decided to halt the Phase 3 UplighTED studies of efgartigimod for moderate to severe thyroid eye disease after an Independent Data Monitoring Committee recommended stopping the trials for futility based on interim analysis data.
Safety Profile: Despite the discontinuation, efgartigimod demonstrated a favorable safety and tolerability profile, with no new safety signals identified during the trials.
Future Data Analysis: Following the closure of the studies, Argenx plans to conduct a comprehensive analysis of the collected data, which will be shared at a future medical meeting.
Market Impact: The announcement surprised analysts, with some noting that the news could positively affect the IGF-1R antibody class, while Argenx shares fell by nearly 5% following the news.
See More
